La chaîne d'options affiche les données clés des options sur actions de Phibro Animal Health à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Phibro Animal Health..

Phibro Animal Health (NASDAQ:PAHC) Stock, Chaîne d'Options

Phibro Animal Health

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

JPMorgan upgraded Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>), citing strong execution following its $350 million acquisition of Zoetis' medicated feed additive and <a href="https://www.benzinga.com/calendars/m-a">water-soluble product portfolio</a>. 
The deal includes 37 product lines sold in about 80 countries, six manufacturing sites across the U.S., Italy, and China. 
Analysts expect the portfolio to enhance Phibro's profitability, improve EBITDA margins, and be accretive to adjusted earnings per share.
Also Read: <a href="https://www.benzinga.com/25/02/43786177/zoetis-avian-influenza-vaccine-secures-conditional-approval-in-us-for-use-in-chickens" target="_blank" rel="noreferrer noopener">Zoetis Avian Influenza Vaccine Secures Conditional Approval In US For Use In Chickens</a>
Analyst Ekaterina V Knyazkova on Monday wrote that animal health performance has exceeded expectations for 2025 supported by strong demand, price increases and healthy growth across MFAs, Nutritional Specialties and Vaccines for 2026.
In the animal health industry, growth in livestock is slower than in companion animals, and this trend is likely to continue, Knyazkova added.
However, the livestock sector still has strong fundamentals—such as population growth, rising meat consumption, and limited impact from economic shifts. Phibro Animal Health stands to benefit following the acquisition of Zoetis' medicated feed additives business. 
In the third quarter of 2025, the company&#8217;s sales reached $347.8 million, an increase of $84.6 million, or 32% year over year, <a href="https://www.benzinga.com/pressreleases/25/05/b45267584/phibro-animal-health-corporation-reports-third-quarter-results-updates-financial-guidance" target="_blank" rel="noreferrer noopener">missing the consensus of $352.40 million</a>.
Adjusted earnings was 63 cents, beating the consensus of 52 cents.
Phibro Animal Health raised its fiscal 2025 adjusted earnings per share guidance from $1.87-$2.01 to $1.96-$2.09 compared to <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $1.94</a>.
It revised its sales guidance from $1.25 billion-$1.30 billion to $1.26 billion-$1.29 billion versus consensus of $1.28 billion.
Analyst Knyazkova writes, &#8220;And while PAHC shares have had a strong run this year, we continue to see a favorable setup from here between the upside to estimates and the still-attractive valuation.&#8221;
Price Action: PAHC stock is up 8.57% at $30.40 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46280221/vice-stocks-beat-esg-trump-2025" target="_blank" rel="noreferrer noopener">Guns, Booze, And Gambling Stocks Are Crushing ESG In Trump&#8217;s America</a></li>
</ul>
Image: Shutterstock

Analyst Color

News

Upgrades

Health Care

Analyst Ratings

Movers

Trading Ideas

General

PAHC

Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan raised Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) price target from $25 to $35. JP Morgan analyst Ekaterina Knyazkova upgraded the stock from Neutral to Overweight. Phibro Animal Health shares closed at $28.00 on Thursday. See how other analysts view this stock.</li>
<li>Jefferies cut the price target for ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) from $53 to $42. Jefferies analyst Surinder Thind downgraded the stock from Hold to Underperform. ASGN shares closed at $52.84 on Thursday. <a href="https://www.benzinga.com/quote/ASGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) price target from $51 to $57. Raymond James analyst Michael Rose upgraded the stock from Outperform to Strong Buy. U.S. Bancorp shares closed at $47.93 on Thursday. <a href="https://www.benzinga.com/quote/USB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised the price target for Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from $194 to $205. Jefferies analyst Kaumil Gajrawala upgraded the stock from Hold to Buy. Constellation Brands shares closed at $172.32 on Thursday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased the price target for MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) from $32 to $33. Jefferies analyst Laurence Alexander downgraded the stock from Buy to Hold. MP Materials shares closed at $31.84 on Thursday. <a href="https://www.benzinga.com/quote/MP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) price target from $4.9 to $7.2. Jefferies analyst Julien Dumoulin-Smith upgraded the stock from Hold to Buy. Shoals Technologies shares settled at $5.98 on Thursday. <a href="https://www.benzinga.com/quote/shls/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) price target from $16.5 to $11.75. B of A Securities analyst Michael Jacks downgraded the stock from Buy to Neutral&nbsp;. Stellantis shares closed at $10.31 on Thursday. <a href="https://www.benzinga.com/quote/STLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $150 to $175. B of A Securities analyst Koji Ikeda maintained a Buy rating. Datadog shares closed at $155.15 on Thursday.  <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) from $321 to $298. Barclays analyst Alex Scott downgraded the stock from Overweight to Equal-Weight. Chubb shares settled at $283.80 on Thursday. <a href="https://www.benzinga.com/quote/CB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised XPO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NASDAQ">XPO</a>) price target from $139 to $150. B of A Securities analyst Ken Hoexter maintained a Buy rating. XPO shares closed at $132.13 on Thursday. <a href="https://www.benzinga.com/quote/XPO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying USB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/USB/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-1024x602.png" alt="" class="wp-image-974719" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Price Target

Markets

ASGN

DDOG

DKNG

NVDA

SHLS

STLA

U.S. Bancorp To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

As of July 7, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Apogee Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)</h3>
<ul class="wp-block-list">
<li>On July 6, Apogee Therapeutics disclosed positive 16-week data from Phase 2 APEX clinical trial of APG777, its potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis. &#8220;With two out of every three patients treated with APG777 achieving EASI-75 response at Week 16 in the Phase 2 APEX Part A trial, APG777 demonstrated the highest EASI-75 response rate both on a topline and placebo-adjusted basis for any biologic in a global study to date, reinforcing its potential best-in-class profile for patients with moderate-to-severe atopic dermatitis,&#8221; said Michael Henderson, M.D., Chief Executive Officer of Apogee. The company's stock jumped around 18% over the past month and has a 52-week high of $63.50.</li>
<li>RSI Value: 84.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>APGE Price Action: Shares of Apogee Therapeutics gained 7.1% to close at $47.46 on Thursday.</li>
<li>Edge Stock Ratings: 70.45 Momentum score </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/apge"><img loading="lazy" decoding="async" width="422" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59.png" alt="" class="wp-image-974595" style="width:274px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59.png 422w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07071721/image-59-300x130.png 300w" sizes="(max-width: 422px) 100vw, 422px" /></a></figure>
<h3 class="wp-block-heading">Phibro Animal Health Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>)</h3>
<ul class="wp-block-list">
<li>On June 25, Morgan Stanley analyst Erin Wright maintained Phibro Animal Health with an Equal-Weight rating and raised the price target from $21 to $26. The company's stock gained around 16% over the past month and <a href="https://www.benzinga.com/quote/PAHC">has a 52-week high</a> of $28.49.</li>
<li>RSI Value: 81.7</li>
<li>PAHC Price Action: Shares of Phibro Animal Health gained 0.2% to close at $28.00 on Thursday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>.
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a></li>
</ul>

Short Ideas

Pre-Market Outlook

APGE

Top 2 Health Care Stocks That May Plunge This Month

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Kaumil Gajrawala upgraded the rating for Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Hold to Buy and raised the price target from $194 to $205. Constellation Brands shares closed at $172.32 on Thursday. <a href="https://www.benzinga.com/quote/stz/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Michael Rose upgraded U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Outperform to Strong Buy and raised the price target from $51 to $57. U.S. Bancorp shares closed at $47.93 on Thursday. <a href="https://www.benzinga.com/quote/usb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith upgraded the rating for Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) from Hold to Buy and lifted the price target from&nbsp;$4.9&nbsp;to&nbsp;$7.2. Shoals Technologies shares closed at $5.98 on Thursday. <a href="https://www.benzinga.com/quote/shls/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ekaterina Knyazkova upgraded Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) from Neutral to Overweight and raised the price target from $25 to $35. Phibro Animal Health shares closed at $28.00 on Thursday. <a href="https://www.benzinga.com/quote/pahc/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying STZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/stz/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-1024x575.png" alt="" class="wp-image-974676" style="width:607px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07081437/image-63.png 1145w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

OSCR

SNDK

VOYG

This Constellation Brands Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

JP Morgan analyst Ekaterina Knyazkova upgrades Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) from Neutral to Overweight and raises the price target from $25 to $35.

JP Morgan Upgrades Phibro Animal Health to Overweight, Raises Price Target to $35

Morgan Stanley analyst Erin Wright maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Equal-Weight and raises the price target from $21 to $26.

Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Raises Price Target to $26

Morgan Stanley analyst Erin Wright maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Equal-Weight and raises the price target from $20 to $21.

Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Raises Price Target to $21

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) raises FY2025 GAAP EPS guidance from $0.96-$1.11 to $0.98-$1.11 vs $1.27 analyst estimate..

Guidance

Phibro Animal Health Raises FY2025 GAAP EPS Guidance from $0.96-$1.11 to $0.98-$1.11 vs $1.27 Est

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) raises FY2025 Adj EPS guidance from $1.87-$2.01 to $1.96-$2.09 vs $1.94 analyst estimate. Narrows FY2025 sales outlook from $1.25 billion-$1.30 billion to $1.26 billion-$1.29 billion vs $1.28 billion estimate.

Phibro Animal Health Raises FY2025 Adj EPS Guidance from $1.87-$2.01 to $1.96-$2.09 vs $1.94 Est; Narrows FY2025 Sales Guidance from $1.25B-$1.30B to $1.26B-$1.29B vs $1.28B Est

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.52 by 21.15 percent. This is a 103.23 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $347.80 million which missed the analyst consensus estimate of $352.40 million by 1.31 percent. This is a 32.14 percent increase over sales of $263.20 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Phibro Animal Health Q3 Adj. EPS $0.63 Beats $0.52 Estimate, Sales $347.80M Miss $352.40M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Here are two stocks with buy rank and strong value characteristics for investors to consider today, February 14th:
Adtalem Global Education Inc. ATGE: This workforce solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.6% over the last 60 days.
<div class="chart_embed">
<h3>Adtalem Global Education Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/ATGE/price-consensus-chart?icid=chart-ATGE-price-consensus-chart"><img alt="Adtalem Global Education Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/56/1739522157.png" style="height:264px; width:573px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/ATGE/price-consensus-chart?icid=chart-ATGE-price-consensus-chart">Adtalem Global Education Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/ATGE?icid=chart-ATGE-price-consensus-chart">Adtalem Global Education Inc. Quote</a>
</div>
Adtalem has a price-to-earnings ratio (P/E) of 17.38, compared with 23.50 for the industry. The company possesses a <a href="https://www.zacks.com/style-scores-education/">Value Score</a>&nbsp; of B.
<div class="chart_embed">
<h3>Adtalem Global Education Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/ATGE/fundamental/pe-ratio-ttm?icid=chart-ATGE-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/cd/1739522299.png&quot; title=&quot;&quot; width=&quot;533&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/ATGE/fundamental/pe-ratio-ttm?icid=chart-ATGE-fundamental/pe-ratio-ttm">Adtalem Global Education Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/ATGE?icid=chart-ATGE-fundamental/pe-ratio-ttm">Adtalem Global Education Inc. Quote</a>
</div>
Phibro Animal Health Corporation PAHC: This animal health and mineral nutrition company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.
<div class="chart_embed">
<h3>Phibro Animal Health Corporation Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/PAHC/price-consensus-chart?icid=chart-PAHC-price-consensus-chart"><img alt="Phibro Animal Health Corporation Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/ce/1739522170.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/PAHC/price-consensus-chart?icid=chart-PAHC-price-consensus-chart">Phibro Animal Health Corporation price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/PAHC?icid=chart-PAHC-price-consensus-chart">Phibro Animal Health Corporation Quote</a>
</div>
Phibro has a price-to-earnings ratio (P/E) of 14.41, compared with 21.88 for the S&amp;P 500. The company possesses a Value Score of A.
<div class="chart_embed">
<h3>Phibro Animal Health Corporation PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/PAHC/fundamental/pe-ratio-ttm?icid=chart-PAHC-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/25/1739522333.png&quot; title=&quot;&quot; width=&quot;533&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/PAHC/fundamental/pe-ratio-ttm?icid=chart-PAHC-fundamental/pe-ratio-ttm">Phibro Animal Health Corporation pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/PAHC?icid=chart-PAHC-fundamental/pe-ratio-ttm">Phibro Animal Health Corporation Quote</a>
</div>
&nbsp;
See <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the full list of top ranked stocks here.</a>
&nbsp;
Learn more about the <a href="https://www.zacks.com/education/stock-scorecard/value-trading">Value score and how it is calculated here.</a>
&nbsp;
<h2>7 Best Stocks for the Next 30 Days</h2>
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers &quot;Most Likely for Early Price Pops.&quot;
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention.&nbsp;
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1473&amp;adid=SYND_BENZ_ZU_7BESTREPORTA_ZACKS1RANKADDITIONS_268_02142025_2415912&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912" style="font-weight:bold">See them now &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_268_2415912&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PAHC&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2415912_PAHC&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912">Phibro Animal Health Corporation (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=ATGE&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2415912_ATGE&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912">Adtalem Global Education Inc. (ATGE): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/commentary/2415912/best-value-stocks-to-buy-for-february-14th?cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2415912">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Equities

Small Cap

Best Value Stocks To Buy For February 14th

WIIM

Phibro Animal Health shares are trading higher after Barclays raised its price target on the stock from $20 to $22.

Rumors

Watching Phibro Animal Health; Hearing Popular Retail Trading Newsletter Picks Stock

Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) with a Underweight and raises the price target from $20 to $22.

Barclays Maintains Underweight on Phibro Animal Health, Raises Price Target to $22

Phibro Animal Health shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) raises FY2025 Adj EPS guidance from $1.34-1.48 to $1.87-2.01 vs $1.64 analyst estimate. Raises FY2025 sales outlook from $1.05 billion-1.10 billion to $1.25 billion-1.30 billion vs $1.27 billion estimate.

Phibro Animal Health Raises FY2025 Adj EPS Guidance from $1.34-1.48 to $1.87-2.01 vs $1.64 Est; Raises FY2025 Sales Guidance from $1.05B-1.10B to $1.25B-1.30B vs $1.27B Est

Phibro Animal Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.42 by 28.57 percent. This is a 63.64 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $309.30 million which beat the analyst consensus estimate of $303.84 million by 1.80 percent. This is a 23.77 percent increase over sales of $249.90 million the same period last year.

Phibro Animal Health Q2 Adj $0.54 Beats $0.42 Estimate, Sales $309.30M Beat $303.84M Estimate

Phibro Sees FY25 Revenue $1.257B-$1.30B Vs $1.27B Estimate

Phibro Animal Health Q2 2025 Adj EPS $0.54 Beats $0.42 Estimate, Sales $309.30M Beat $303.84M Estimate

Press Releases

Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results

Phibro Animal Health Corporation Announces the Appointment of Joyce J. Lee to Its Board of Directors

Phibro Animal Health Corporation Declares Quarterly Dividend

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

Phibro Animal Health Corporation to Participate at Bank of America 2025 Virtual Animal Health Summit

Phibro Animal Health Corporation to Participate at Barclays Annual Global Healthcare Conference

Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results

Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance

Phibro Animal Health Corporation to Participate at Stifel Jaws & Paws Conference

Comments

Phibro Animal Health

Phibro Animal Health (PAHC) Options

Phibro Animal Health (NASDAQ:PAHC) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL